Certified Researchers

Psoriasis Treatment Market Summary

According to Market Research Future analysis, the Psoriasis Treatment Market Size was valued at USD 28.6 Billion in 2025 & the market is projected to grow from USD 31.2 Billion in 2026 to USD 68.80 Billion by 2035, registering a CAGR of 9.2% during the forecast period 2026–2035. North America led the market with over 45% share, generating around USD 12.87 billion in revenue.

Rising global prevalence of psoriasis and other chronic inflammatory skin conditions is a major growth driver, supported by increasing awareness, improved diagnosis rates, and growing demand for advanced therapies, significantly accelerating adoption of effective and targeted psoriasis treatment solutions worldwide.

According to WHO, psoriasis affects approximately 2–3% of the global population, representing over 125 million people worldwide, while IHME reports skin diseases contribute to more than 42 million years lived with disability (YLDs) globally, highlighting strong and sustained demand for effective psoriasis treatment solutions.

Key Market Trends & Highlights

The Psoriasis Treatment Market is experiencing a transformative shift towards innovative therapies and personalized care.

North America leads with over 45% revenue share in 2025, driven by high prevalence and advanced biologic adoption.
Europe accounted for USD 8.58 billion in 2025, holding 30% share supported by strong healthcare systems and awareness.
Psoriasis affects over 125 million people globally, significantly driving long-term demand for advanced and effective treatment solutions.
Topical treatments dominate with 48% share in 2024, supported by accessibility and effectiveness in mild-to-moderate psoriasis cases.

Market Size & Forecast

2025 Market Size	28.6 (USD Billion)
2035 Market Size	68.8 (USD Billion)
CAGR (2025 - 2035)	9.2%

Major Players

Companies such as AbbVie (US), Amgen (US), Johnson & Johnson (US), Novartis (CH), Bristol-Myers Squibb (US), GSK (GB), Eli Lilly (US), Sanofi (FR), UCB (BE) are some of the major participants in the global market.

Our Impact

Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals

Partnering with 2000+ Global Organizations Each Year

30K+ Citations by Top-Tier Firms in the Industry

Psoriasis Treatment Market Trends

The Psoriasis Treatment Market is currently experiencing a dynamic evolution, driven by a combination of innovative therapies and a growing understanding of the disease's underlying mechanisms. Recent advancements in biologic treatments, which target specific pathways involved in the inflammatory process, appear to be reshaping the therapeutic landscape. Additionally, psoriasis statistics suggest that the increasing prevalence of psoriasis globally suggests a rising demand for effective treatment options.

This trend is further supported by heightened awareness and education surrounding the condition, which encourages patients to seek medical advice and explore available therapies. Moreover, the market is witnessing a shift towards personalized medicine, where treatments are tailored to individual patient profiles. This approach not only enhances treatment efficacy but also minimizes potential side effects, thereby improving patient adherence, augmenting the psoriasis market size.

The integration of digital health technologies, such as telemedicine and mobile health applications, is also gaining traction, facilitating better patient management and follow-up care. As the market continues to evolve, stakeholders must remain vigilant to emerging trends and adapt strategies accordingly to meet the diverse needs of patients and healthcare providers alike.

Rise of Biologic Therapies

The Psoriasis Treatment Market is increasingly characterized by the emergence of biologic therapies. Psoriasis statistics suggest that these advanced treatments target specific components of the immune system, offering a more effective approach to managing psoriasis symptoms. As research progresses, the development of new biologics is likely to expand treatment options, potentially leading to improved patient outcomes.

According to CDC and WHO data, autoimmune diseases affect nearly 5–8% of the global population, while biologic therapies have demonstrated efficacy rates exceeding 70% improvement in psoriasis severity (PASI 75) in clinical studies, supporting strong adoption of targeted biologic treatments in managing moderate-to-severe psoriasis cases.

Personalized Medicine Approach

There is a noticeable shift towards personalized medicine within the Psoriasis Treatment Market. Tailoring treatments to individual patient characteristics may enhance therapeutic effectiveness and reduce adverse effects. This trend suggests a growing recognition of the need for customized care in managing chronic conditions like psoriasis.

IHME reports that chronic diseases account for over 41 million deaths annually, while WHO highlights that personalized treatment approaches can improve therapeutic outcomes by up to 30%, reinforcing the shift toward individualized psoriasis care strategies that enhance effectiveness and minimize adverse reactions.

Integration of Digital Health Solutions

The incorporation of digital health solutions is transforming the Psoriasis Treatment Market. Telemedicine and mobile applications are facilitating better patient engagement and monitoring. This trend indicates a move towards more accessible and efficient healthcare delivery, which could significantly improve treatment adherence and patient satisfaction.

According to UNICEF, over 5.3 billion people globally use the internet, while WHO reports telemedicine utilization increased by more than 25% in recent years, enabling improved remote monitoring, adherence, and patient engagement in chronic disease management, including psoriasis treatment and long-term care solutions.

Psoriasis Treatment Market Drivers

Growing Awareness and Education

The increasing awareness and education surrounding psoriasis are crucial drivers for the Psoriasis Treatment Market. Campaigns aimed at educating the public about the condition and its treatment options have led to a rise in diagnosis rates. Patients are now more informed about their treatment choices, which encourages them to seek medical advice.

This heightened awareness is particularly evident in regions where healthcare initiatives focus on chronic diseases. As more individuals understand the implications of psoriasis, the demand for effective treatments is expected to rise, thereby propelling the market forward.

Increasing Prevalence of Psoriasis

The rising incidence of psoriasis is a pivotal driver in the Psoriasis Treatment Market. Recent estimates indicate that approximately 2-3% of the population is affected by this chronic skin condition, leading to a growing demand for effective treatment options.

As awareness of psoriasis increases, more individuals seek medical intervention, thereby expanding the market. The prevalence of psoriasis is particularly notable in developed regions, where healthcare access is more readily available. This trend suggests that the market will continue to grow as healthcare providers develop new therapies to meet the needs of an expanding patient population.

Advancements in Treatment Modalities

Innovations in treatment modalities are significantly influencing the Psoriasis Treatment Market. The introduction of biologic therapies, which target specific pathways in the immune system, has transformed the treatment landscape. These therapies have shown efficacy in moderate to severe cases, leading to increased adoption among healthcare professionals.

Furthermore, the market is witnessing a surge in topical treatments and systemic therapies, which cater to varying degrees of psoriasis severity. The continuous research and development efforts in this area indicate a promising future for the market, as new and improved therapies are likely to emerge.

Regulatory Support for New Therapies

Regulatory support for the approval of new therapies is a vital driver in the Psoriasis Treatment Market. Regulatory agencies are increasingly expediting the review process for innovative treatments, particularly biologics and novel systemic therapies. This trend is encouraging pharmaceutical companies to invest in research and development, leading to a more diverse array of treatment options for patients.

The favorable regulatory environment not only accelerates the availability of new therapies but also enhances competition within the market. As a result, the market is likely to experience growth as new and effective treatments become accessible to patients.

Rising Investment in Healthcare Infrastructure

The expansion of healthcare infrastructure is a significant factor impacting the Psoriasis Treatment Market. Increased investment in healthcare facilities and services enhances access to dermatological care, which is essential for effective psoriasis management.

Governments and private entities are focusing on improving healthcare systems, particularly in underserved areas. This investment is likely to facilitate better diagnosis and treatment options for psoriasis patients. As healthcare systems evolve, the market is poised to benefit from improved patient access and a broader range of treatment modalities.

Market Segment Insights

By Type: Topical Treatments (Largest) vs. Biologics (Fastest-Growing)

The Topical Treatments segment dominates the Psoriasis Treatment Market share at 48% due to its widespread use and accessibility for patients. This segment includes various therapies such as corticosteroids, vitamin D analogs, and retinoids, which are effective for mild to moderate cases of psoriasis. On the other hand, Biologics, which are advanced medications targeting specific parts of the immune system, are gaining traction and hold a significant part of the market due to their effectiveness in severe cases, resulting in their rapid growth.

Topical Treatments (Dominant) vs. Biologics (Emerging)

Topical Treatments have established themselves as the cornerstone for managing psoriasis for many patients, especially those with mild to moderate conditions. These treatments are often preferred due to their ease of use, direct application, and lower risk of systemic side effects. In contrast, Biologics represent an emerging avenue in psoriasis therapy, offering targeted relief for moderate to severe cases through innovative methods that inhibit inflammatory pathways. Their increasing effectiveness and the medical community's growing familiarity with these drugs are driving rapid adoption. As a result, while Topical Treatments remain dominant, Biologics are set to capture a larger share of the market, owing to a favorable outlook and endorsement from dermatology guidelines.

By Administration Route: Topical (Largest) vs. Injectable (Fastest-Growing)

The administration route segment displays significant diversity, with topical treatments holding the largest Psoriasis Treatment Market share at 52%. These treatments are favored due to their direct application on affected areas, resulting in minimal systemic exposure. Injectables, while representing a smaller share currently, are emerging as a potent contender due to their efficacy and the increasing patient and physician acceptance. Oral and intravenous routes, though available, occupy more specialized niches within the market.

Topical (Dominant) vs. Injectable (Emerging)

Topical treatments for psoriasis, including creams, ointments, and gels, dominate the market due to their targeted nature and ease of use. They are widely preferred by patients and healthcare providers for milder cases and are often the first line of defense. Conversely, injectable treatments, such as biologics, are rapidly gaining traction as they offer significant relief for moderate to severe psoriasis. They harness advanced biotechnology and have shown impressive efficacy rates, making them an attractive option for treatment-resistant patients. This shift towards injectables represents a growing trend in the market, driven by continued advancements in technology and the increasing prevalence of psoriasis.

By Indication: Plaque Psoriasis (Largest) vs. Guttate Psoriasis (Fastest-Growing)

The psoriasis treatment market features a diverse range of indications, with Plaque Psoriasis accounting for the largest market share at 62%. This subtype is the most prevalent form of psoriasis and is characterized by raised, inflamed lesions covered with silvery scales. Guttate Psoriasis, while smaller in share compared to Plaque, has been noted for its rapid growth, primarily in younger populations and influenced by factors such as streptococcal infections. As the awareness and diagnosis of various psoriasis types improve, the market distribution reflects these changes in patient demographics and symptom presentations.

Plaque Psoriasis (Dominant) vs. Guttate Psoriasis (Emerging)

Plaque Psoriasis remains the dominant indication in the market, largely due to its high prevalence and the extensive range of effective therapies available. Patients with Plaque Psoriasis often experience chronic symptoms, leading to consistent demand for treatment options. In contrast, Guttate Psoriasis is emerging quickly, especially among adolescents and young adults, as it is often a result of infections or stress. While it may not be as well-known as Plaque, the increasing incidence rates and novel treatment approaches are propelling its market presence. Patients with Guttate are generally more receptive to new therapies, creating opportunities for innovative treatment options.

By End User: Hospital (Largest) vs. Dermatology Clinics (Fastest-Growing)

Hospitals account for the largest share in the psoriasis treatment market, representing 46% of the end-user segment. This is primarily due to their capacity to offer comprehensive care, advanced treatment options, and the availability of specialist healthcare professionals. Dermatology clinics follow closely, yet they are witnessing an impressive surge in demand as more patients seek specialized care in a focused environment. Homecare settings are becoming increasingly relevant, particularly for those preferring convenience and personalized treatment regimens, although they hold a smaller share compared to hospitals and clinics.

Dermatology Clinics (Dominant) vs. Homecare Settings (Emerging)

Dermatology clinics serve as a dominant force in the market due to their targeted approach to skincare and treatment of specific conditions, which resonates well with patients seeking expert help. They not only provide customized treatment plans and access to cutting-edge therapies but also facilitate continuous monitoring of patients' progress, enhancing treatment efficacy. Conversely, homecare settings are emerging as a vital alternative, especially amid the growing trend of telemedicine and patient-centric care models. The convenience of managing psoriasis treatments at home appeals to many patients, especially those with mild to moderate conditions, thus fostering growth opportunities in this segment.

Get more detailed insights about Psoriasis Treatment Market

Request Free Sample

Regional Insights

North America : Leading Market for Treatments

North America leads in the Psoriasis Treatment Market size, accounting for over 45% of the global revenue in 2025. The region's growth is driven by increasing prevalence of psoriasis, advancements in treatment options, and supportive regulatory frameworks. The U.S. Food and Drug Administration (FDA) has accelerated the approval process for innovative therapies, enhancing market dynamics.

According to CDC, over 7.5 million people in the U.S. are affected by psoriasis, while healthcare expenditure exceeds USD 4.5 trillion annually, supporting widespread access to advanced therapies and accelerating adoption of innovative psoriasis treatment solutions across the region.

The demand for biologics and targeted therapies is on the rise, further propelling market growth. The competitive landscape in North America is robust, with key players such as AbbVie, Amgen, and Johnson & Johnson leading the market. The presence of advanced healthcare infrastructure and high healthcare expenditure supports the adoption of new therapies. Additionally, ongoing clinical trials and research initiatives are expected to introduce novel treatment options, solidifying North America's position as a leader in the market.

Europe : Emerging Market with Growth Potential

Europe Psoriasis Treatment Market size was valued at USD 8.58 billion in 2025, making it the second-largest regional market with a 30% share. The region is witnessing significant growth due to rising awareness about psoriasis, increasing healthcare investments, and favorable reimbursement policies. The European Medicines Agency (EMA) has been proactive in approving new therapies, which has stimulated market demand.

According to ECDC and WHO Europe, psoriasis affects approximately 14 million people in Europe, while healthcare spending accounts for nearly 10% of GDP, supporting improved access to advanced dermatological treatments and strengthening demand for effective psoriasis therapies across the region.

The growing focus on personalized medicine is also a key driver of market expansion in Europe. Leading countries in Europe include Germany, France, and the UK, which are home to several prominent pharmaceutical companies. Key players such as Novartis, GSK, and Sanofi are actively involved in developing innovative treatments. The competitive landscape is characterized by a mix of established companies and emerging biotech firms, fostering a dynamic environment for psoriasis treatment advancements.

Asia-Pacific : Rapidly Growing Treatment Sector

The Asia-Pacific region is emerging as a significant player in the psoriasis treatment market, accounting for approximately 20% of the global market share. The growth is driven by increasing awareness of skin diseases, rising disposable incomes, and expanding healthcare access. Countries like China and India are witnessing a surge in demand for psoriasis treatments, supported by government initiatives aimed at improving healthcare infrastructure and access to medications.

Regulatory bodies are also streamlining approval processes for new therapies, enhancing market dynamics. In the competitive landscape, key players such as Eli Lilly and Pfizer are making substantial investments in the region. The presence of local pharmaceutical companies is also increasing, contributing to a diverse market. The growing trend of telemedicine and digital health solutions is expected to further boost treatment accessibility and patient engagement in the Asia-Pacific region, driving future growth.

Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa (MEA) region is gradually developing its psoriasis treatment market, holding approximately 5% of the global market share. The growth is hindered by challenges such as limited healthcare infrastructure, high treatment costs, and varying levels of awareness about psoriasis. However, increasing investments in healthcare and initiatives to improve access to treatments are expected to drive market growth in the coming years. Regulatory bodies are working to enhance the approval processes for new therapies, which could stimulate market dynamics.

Leading countries in the MEA region include South Africa and the UAE, where there is a growing presence of international pharmaceutical companies. Key players are beginning to explore opportunities in this region, focusing on affordable treatment options. The competitive landscape is evolving, with local firms collaborating with global companies to enhance treatment availability and awareness, paving the way for future growth in the market.

Psoriasis Treatment Market Regional Image

Key Players and Competitive Insights

The Psoriasis Treatment Market is characterized by a dynamic competitive landscape, driven by a confluence of innovation, strategic partnerships, and a growing emphasis on personalized medicine. Major players such as AbbVie (US), Amgen (US), and Novartis (CH) are at the forefront, leveraging their extensive research capabilities and established market presence to enhance their product offerings. AbbVie (US) continues to focus on its flagship product, Humira, while also investing in the development of new therapies that target specific patient populations. Meanwhile, Amgen (US) is expanding its portfolio through strategic collaborations aimed at enhancing its biologics pipeline, which is crucial in addressing the diverse needs of psoriasis patients. Novartis (CH) is similarly positioned, emphasizing its commitment to innovation through the development of novel therapies that not only improve efficacy but also reduce treatment burden for patients.

In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the psoriasis treatment market appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for a diverse range of treatment options, catering to different patient demographics and preferences, while also fostering a competitive environment that encourages continuous innovation.

In August 2025, AbbVie (US) announced a strategic partnership with a leading biotechnology firm to co-develop a new class of oral therapies for psoriasis. This collaboration is expected to accelerate the development timeline and enhance AbbVie’s competitive edge in the oral treatment segment, which is gaining traction among patients seeking alternatives to injectable therapies. The strategic importance of this partnership lies in its potential to broaden AbbVie’s market share and reinforce its position as a leader in psoriasis treatment.

In September 2025, Amgen (US) launched a new digital health platform aimed at improving patient engagement and adherence to psoriasis treatments. This initiative reflects a growing trend towards digitalization in healthcare, where technology is leveraged to enhance patient outcomes. By integrating digital tools into its treatment protocols, Amgen (US) not only improves patient experience but also gathers valuable data that can inform future product development.

In October 2025, Novartis (CH) unveiled a sustainability initiative focused on reducing the environmental impact of its manufacturing processes for psoriasis treatments. This move aligns with the increasing demand for sustainable practices within the pharmaceutical industry and positions Novartis as a forward-thinking player committed to corporate social responsibility. The strategic importance of this initiative is multifaceted, as it not only addresses regulatory pressures but also resonates with environmentally conscious consumers.

As of October 2025, the competitive trends in the psoriasis treatment market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex market dynamics. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability, ultimately enhancing patient care and treatment outcomes.

Key Companies in the Psoriasis Treatment Market include

Industry Developments

In recent months, the Global Psoriasis Treatment Market has experienced significant developments, particularly with companies like AbbVie making strides in Research and Development for improved biologic therapies. In September 2023, Pfizer launched a new clinical trial aimed at exploring innovative treatments for moderate to severe psoriasis, showcasing ongoing commitment in this sector. Similarly, in August 2023, Merck announced advancements in their psoriasis portfolio, aimed at enhancing patient outcomes.

Major companies including Johnson and Johnson and Novartis continue to engage in improving treatment options, while GSK has been actively investing in research to tap into emerging treatment modalities. In terms of mergers and acquisitions, in July 2023, AstraZeneca completed the acquisition of a portfolio from a small biotech company focused on skin diseases, significantly enhancing their capabilities in the psoriasis market.

Reports indicate that there is growing momentum for biologic therapies, which has led to increased valuations for key players in the market. Over the past two to three years, the industry has witnessed a marked increase in interest and investment, particularly in targeting more effective treatment options for patients, as the demand for innovative solutions continues to rise globally.

Future Outlook

Psoriasis Treatment Market Future Outlook

The Psoriasis Treatment Market size is projected to reach USD 68.80 Billion by 2035, growing at a CAGR of 9.2%, driven by increasing prevalence, innovative therapies, and rising healthcare expenditure.

New opportunities lie in:

Development of personalized biologic therapies targeting specific patient profiles. Expansion of telehealth services for remote patient monitoring and consultations. Investment in digital health platforms for treatment adherence and education.

By 2035, the Psoriasis Treatment Market is expected to achieve substantial growth and innovation.

Market Segmentation

Psoriasis Treatment Market Type Outlook

Topical Treatments
Systemic Treatments
Phototherapy
Biologics

Psoriasis Treatment Market End User Outlook

Hospital
Dermatology Clinics
Homecare Settings

Psoriasis Treatment Market Indication Outlook

Plaque Psoriasis
Guttate Psoriasis
Inverse Psoriasis
Pustular Psoriasis

Psoriasis Treatment Market Administration Route Outlook

Oral
Topical
Injectable
Intravenous

Report Scope

MARKET SIZE 2025	28.6(USD Billion)
MARKET SIZE 2026	31.2(USD Billion)
MARKET SIZE 2035	68.8(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	9.2% (2026 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2025
Market Forecast Period	2026 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	AbbVie (US), Amgen (US), Johnson & Johnson (US), Novartis (CH), Bristol-Myers Squibb (US), GSK (GB), Eli Lilly (US), Sanofi (FR), UCB (BE)
Segments Covered	Treatment Type, Administration Route, Indication, End User, Regional
Key Market Opportunities	Emergence of biologics and personalized therapies enhances treatment options in the market.
Key Market Dynamics	Rising demand for biologics drives innovation and competition in the psoriasis treatment landscape.
Countries Covered	North America, Europe, APAC, South America, MEA

Market Highlights

Psoriasis Treatment Companies

FAQs

What is the current valuation of the Psoriasis Treatment Market as of 2024?

The Psoriasis Treatment Market was valued at 7.45 USD Billion in 2024.

What is the projected market size for the Psoriasis Treatment Market by 2035?

The market is projected to reach 12.0 USD Billion by 2035.

What is the expected CAGR for the market during the forecast period 2025 - 2035?

The expected CAGR for the market during 2025 - 2035 is 4.43%.

Which segment of the Psoriasis Treatment Market had the highest valuation in 2024?

In 2024, the Biologics segment had the highest valuation at 2.95 USD Billion.

What are the projected values for Topical Treatments in the Psoriasis Treatment Market by 2035?

Topical Treatments are projected to reach 2.5 USD Billion by 2035.

How does the market for Injectable treatments compare to Oral treatments in 2024?

In 2024, the market for Injectable treatments was valued at 2.0 USD Billion, while Oral treatments were also at 1.5 USD Billion.

What is the expected growth for the Homecare Settings segment by 2035?

The Homecare Settings segment is expected to grow to 5.0 USD Billion by 2035.

Which key players are leading the Psoriasis Treatment Market?

Key players in the market include AbbVie, Amgen, Johnson & Johnson, and Novartis.

What is the projected value of Plaque Psoriasis treatments by 2035?

Plaque Psoriasis treatments are projected to reach 5.0 USD Billion by 2035.

What is the anticipated market performance for Dermatology Clinics in the coming years?

Dermatology Clinics are expected to grow to 3.0 USD Billion by 2035.

Author

Author

Satyendra Maurya

Research Analyst

An accomplished research analyst with high proficiency in market forecasting, data visualization, competitive benchmarking, and others. He holds a pronounced track record in research and consulting projects for sectors such as life sciences, medical devices, and healthcare IT. His capabilities in qualitative and quantitative analysis have resulted in positive client outcomes. Working on niche market trends, opportunities, sales, and forecasted value is part of his skill set.

Co-Author

Rahul Gotadki

Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment

Certified Researchers

Customize Report

Research Approach

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed dermatology and immunology journals, clinical trial registries, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) [Center for Drug Evaluation and Research - Dermatology and Ophthalmology Division], European Medicines Agency (EMA) [Committee for Medicinal Products for Human Use], National Institute for Health and Care Excellence (NICE) UK, Pharmaceuticals and Medical Devices Agency (PMDA) Japan, and Health Canada.

Clinical and epidemiological data were sourced from the National Psoriasis Foundation (NPF) [US epidemiology studies], International Psoriasis Council (IPC), American Academy of Dermatology (AAD), European Academy of Dermatology and Venereology (EADV), and International League of Dermatological Societies (ILDS). Government health statistics were obtained from the Centers for Disease Control and Prevention (CDC) [National Health and Nutrition Examination Survey], National Institutes of Health (NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases - NIAMS), World Health Organization (WHO) [Global Burden of Disease Study], Eurostat Health Database, NHS Digital [UK Hospital Episode Statistics], and Agency for Healthcare Research and Quality (AHRQ) [Medical Expenditure Panel Survey].

Academic and clinical sources included PubMed/MEDLINE, Cochrane Library [Systematic reviews on biologic therapies], ClinicalTrials.gov, EU Clinical Trials Register (EudraCT), and peer-reviewed journals such as Journal of the American Academy of Dermatology (JAAD), British Journal of Dermatology, Journal of Investigative Dermatology, JAMA Dermatology, Lancet Dermatology, and Nature Reviews Rheumatology. These sources were used to collect treatment prevalence data, regulatory approval timelines for biologics/biosimilars, clinical efficacy studies, pipeline analysis for IL-17/IL-23 inhibitors, patient demographic trends, and reimbursement landscapes across treatment modalities.

Primary Research

In order to gather qualitative and quantitative information on treatment acceptance, pricing dynamics, and clinical protocols, supply-side and demand-side stakeholders were interviewed during the primary research phase. CEOs, VPs of Immunology/Inflammation R&D, Heads of Global Regulatory Affairs, and Directors of Commercial Strategy were among the supply-side sources. These included pharmaceutical companies that produced biologics (TNF-alpha inhibitors, IL-17/IL-23 inhibitors), topical therapies (corticosteroids, vitamin D analogs, calcineurin inhibitors), and phototherapy equipment OEMs. Board-certified dermatologists in both academic and community settings, rheumatologists who treat psoriatic arthritis, hospital systems' chief pharmacy officers, dermatology clinic medical directors, homecare nursing supervisors, and procurement leads from specialty pharmacies were among the demand-side sources. Primary research obtained information on formulary placement strategies, prior authorization requirements, and reimbursement dynamics for novel therapies such as oral JAK inhibitors and IL-23 inhibitors, validated market segmentation across treatment types, verified biosimilar pipeline timelines, and evaluated patient adherence patterns for biologic vs. topical therapies.

Primary Respondent Breakdown:

By Designation: C-level Executives (32%), Director Level (30%), Others (38%)

[Others include Senior Managers, Principal Scientists, Medical Affairs Leads, and Specialty Pharmacists]

By Region: North America (38%), Europe (28%), Asia-Pacific (24%), Rest of World (10%)

Market Size Estimation

Global market valuation was derived through pharmaceutical revenue mapping, prescription volume analysis, and procedure-based phototherapy utilization metrics. The methodology included:

Identification of 40+ key pharmaceutical and medical device manufacturers across North America, Europe, Asia-Pacific, Latin America, and Middle East/Africa, including innovators in monoclonal antibodies (IL-17A, IL-12/23, IL-23p19 inhibitors), biosimilar developers, topical formulation specialists, and phototherapy equipment providers.

Product mapping across biologics (originator and biosimilar TNF inhibitors, IL inhibitors), systemic small molecules (methotrexate, cyclosporine, apremilast, deucravacitinib), topical therapies (high-potency corticosteroids, vitamin D3 analogs, fixed-dose combinations, topical calcineurin inhibitors), and phototherapy devices (narrowband UVB, excimer laser systems).

Analysis of reported and modeled annual revenues specific to psoriasis indications, segmented by treatment line (first-line topicals vs. second-line biologics) and severity (mild, moderate, severe).

Coverage of manufacturers representing 75-80% of global market share in 2024, reflecting the concentrated nature of the biologics market dominated by major immunology players.

Extrapolation using bottom-up (diagnosed prevalent patient population × treatment penetration rates × average treatment cost by country/severity) and top-down (pharmaceutical company reported revenue validation, adjusted for psoriasis-specific indication where available) approaches to derive segment-specific valuations for biologics, biosimilars, and conventional therapies.

Price elasticity modeling for biosimilar entry scenarios and formulary placement impact across hospital, dermatology clinic, and homecare administration settings.